Brigatinib is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Brigatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Brigatinib overview
Brigatinib (AP-26113, Alunbrig, Evobrig) is an anti-neoplastic agent. It is formulated as film coated tablets, tablets for oral route of administration. Brigatinib is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib, or previously treated with crizotinib, and also as a first-line treatment option for adult patients diagnosed with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.Alunbrig is indicated without conditions as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) and patients with ALK fusion gene-positive, advanced / recurrent solid tumors excluding non-small cell lung cancer.
See Also:
It is also under development for the treatment of neurofibromatosis type 2 (NF2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas and ependymomas. It was also under development for anaplastic large cell lymphoma, diffuse large B cell lymphoma, metastatic brain tumors and inflammatory myofibroblastic tumor.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary of Takeda Pharmaceutical Co Ltd, is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. Takeda Oncology is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Brigatinib’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
